Skip to main content
Erschienen in: Endocrine 2/2017

31.12.2016 | Review

Insights into the relationships between diabetes, prediabetes, and cancer

verfasst von: Lorenzo Scappaticcio, Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito

Erschienen in: Endocrine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Diabetes mellitus and cancer are two growing health problems. They have in common many modifiable risk factors including sex, age, obesity, physical activity, diet, alcohol, and smoking, and have a long latency before overtly manifesting. Patients with diabetes experience a roughly 20–25% higher cancer incidence compared to individuals without diabetes, and it depends on cancer site. Moreover, patients with diabetes who further develop cancer have increased early and late mortality in comparison with cancer patients without diabetes. Prediabetes and metabolic syndrome are also related to an increased risk of developing and die from cancer. Possible mechanisms linking diabetes and prediabetes with cancer include hyperglycemia (endogenous or exogenous), hyperinsulinemia, and alterations of insulin-like growth factor system, chronic subclinical inflammation, abnormalities in sex hormone metabolism, and adipokines. It becomes crucial to define the right orientation of the associations between diabetes and cancer in order to identify the modifiable pathogenic mechanisms. The common soil hypothesis claims that prediabetes and diabetes, as well as metabolic syndrome, may be considered a surrogate sign for dietary risk factors of cancer. The clepsydra of foods may help choose foods associated with healthy benefit while avoiding foods associated with harm, including cancer.
Literatur
2.
Zurück zum Zitat World Health Organization (WHO), International Agency for Research on Cancer (IARC)—GLOBOCAN 2012 and Cancer fact sheets World Health Organization (WHO), International Agency for Research on Cancer (IARC)—GLOBOCAN 2012 and Cancer fact sheets
3.
Zurück zum Zitat World Health Organization (WHO), Cancer fact sheet N° 97 Updated February 2015 World Health Organization (WHO), Cancer fact sheet N° 97 Updated February 2015
4.
Zurück zum Zitat E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. Albright, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modeling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. Albright, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modeling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed
5.
Zurück zum Zitat P. Vineis, C.P. Wild, Global cancer patterns: causes and prevention. Lancet 383, 549–557 (2014)CrossRefPubMed P. Vineis, C.P. Wild, Global cancer patterns: causes and prevention. Lancet 383, 549–557 (2014)CrossRefPubMed
6.
Zurück zum Zitat M. Arnold, N. Pandeya, G. Byrnes et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed M. Arnold, N. Pandeya, G. Byrnes et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed
7.
Zurück zum Zitat S.A. Tanumihardjo, C. Anderson, M. Kaufer-Horwitz et al. Poverty, obesity, and malnutrition: an international perspective recognizing the paradox. J. Am. Diet. Assoc. 107, 1966–1972 (2007)CrossRefPubMed S.A. Tanumihardjo, C. Anderson, M. Kaufer-Horwitz et al. Poverty, obesity, and malnutrition: an international perspective recognizing the paradox. J. Am. Diet. Assoc. 107, 1966–1972 (2007)CrossRefPubMed
10.
Zurück zum Zitat K. Esposito, F. Ciardiello, D. Giugliano, Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46, 39–42 (2014)CrossRefPubMed K. Esposito, F. Ciardiello, D. Giugliano, Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine 46, 39–42 (2014)CrossRefPubMed
11.
Zurück zum Zitat K. Ranc, M.E. Jørgensen, S. Friis, B. Carstensen, Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57(5), 927–934 (2014)CrossRefPubMed K. Ranc, M.E. Jørgensen, S. Friis, B. Carstensen, Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57(5), 927–934 (2014)CrossRefPubMed
12.
Zurück zum Zitat A. Renehan, U. Smith, M.S. Kirkman, Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733), 2201–2 (2010). CrossRefPubMed A. Renehan, U. Smith, M.S. Kirkman, Linking diabetes and cancer: a consensus on complexity. Lancet 375(9733), 2201–2 (2010). CrossRefPubMed
13.
Zurück zum Zitat S.M. Bluethmann, A.B. Mariotto, J.H. Rowland, Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol. Biomarkers Prev. 25(7), 1029–1036 (2016)CrossRefPubMedPubMedCentral S.M. Bluethmann, A.B. Mariotto, J.H. Rowland, Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol. Biomarkers Prev. 25(7), 1029–1036 (2016)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat E.C. de Haas, S.F. Oosting, J.D. Lefrandt et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 11, 193–203 (2010)CrossRefPubMed E.C. de Haas, S.F. Oosting, J.D. Lefrandt et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 11, 193–203 (2010)CrossRefPubMed
15.
16.
Zurück zum Zitat S.C. Darby, M. Ewertz, P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013)CrossRefPubMed S.C. Darby, M. Ewertz, P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013)CrossRefPubMed
17.
Zurück zum Zitat T. Tuffier, Diabete et neoplasmes. Arch. Gen. de Med. 7, 129–140 (1988) T. Tuffier, Diabete et neoplasmes. Arch. Gen. de Med. 7, 129–140 (1988)
18.
Zurück zum Zitat Y. Shi, F.B. Hu, The global implications of diabetes and cancer. Lancet 383(9933), 1947–1948 (2014). 7CrossRefPubMed Y. Shi, F.B. Hu, The global implications of diabetes and cancer. Lancet 383(9933), 1947–1948 (2014). 7CrossRefPubMed
19.
Zurück zum Zitat I.C. Lega, A.S. Wilton, P.C. Austin et al. The temporal relationship between diabetes and cancer. Cancer. 17, 2731–2738 (2016) I.C. Lega, A.S. Wilton, P.C. Austin et al. The temporal relationship between diabetes and cancer. Cancer. 17, 2731–2738 (2016)
20.
Zurück zum Zitat Y. Handelsman, D. Leroith, Z.T. Bloomgarden et al. Diabetes and cancer—an AACE/ACE consensus statement. Endocr. Pract. 19(4), 675–693 (2013)CrossRefPubMed Y. Handelsman, D. Leroith, Z.T. Bloomgarden et al. Diabetes and cancer—an AACE/ACE consensus statement. Endocr. Pract. 19(4), 675–693 (2013)CrossRefPubMed
21.
Zurück zum Zitat A. Satija, D. Spiegelman, E. Giovannucci, F.B. Hu, Type 2 diabetes and risk of cancer. BMJ 2, 350 (2015). g7707 A. Satija, D. Spiegelman, E. Giovannucci, F.B. Hu, Type 2 diabetes and risk of cancer. BMJ 2, 350 (2015). g7707
22.
Zurück zum Zitat C. De Nunzio, A. Tubaro, Prostate cancer: diabetes and prostate cancer - an open debate. Nat. Rev. Urol. 10, 12–14 (2013)CrossRefPubMed C. De Nunzio, A. Tubaro, Prostate cancer: diabetes and prostate cancer - an open debate. Nat. Rev. Urol. 10, 12–14 (2013)CrossRefPubMed
23.
Zurück zum Zitat D. Bansal, A. Bhansali, G. Kapil, K. Undela, P. Tiwari, Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 16, 151–158 (2013). S1CrossRefPubMed D. Bansal, A. Bhansali, G. Kapil, K. Undela, P. Tiwari, Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 16, 151–158 (2013). S1CrossRefPubMed
24.
Zurück zum Zitat K.K. Tsilidis, N.E. Allen, P.N. Appleby et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int. J. Cancer 136, 372–381 (2015)CrossRefPubMed K.K. Tsilidis, N.E. Allen, P.N. Appleby et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int. J. Cancer 136, 372–381 (2015)CrossRefPubMed
26.
Zurück zum Zitat Q. Li, S. Kuriyama, M. Kakizaki et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki cohort study. Cancer Causes Control 21, 1025–1032 (2010)CrossRefPubMed Q. Li, S. Kuriyama, M. Kakizaki et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki cohort study. Cancer Causes Control 21, 1025–1032 (2010)CrossRefPubMed
27.
Zurück zum Zitat L. Bensimon, H. Yin, S. Suissa, M.N. Pollak, L. Azoulay, Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329–338 (2014)CrossRefPubMed L. Bensimon, H. Yin, S. Suissa, M.N. Pollak, L. Azoulay, Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329–338 (2014)CrossRefPubMed
28.
Zurück zum Zitat S.R. Seshasai, S. Kaptoge, A. Thompson et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829–841 (2011)CrossRef S.R. Seshasai, S. Kaptoge, A. Thompson et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829–841 (2011)CrossRef
29.
Zurück zum Zitat R. Dankner, P. Boffetta, R.D. Balicer et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183(12), 1098–1106 (2016). 15CrossRefPubMed R. Dankner, P. Boffetta, R.D. Balicer et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am. J. Epidemiol. 183(12), 1098–1106 (2016). 15CrossRefPubMed
30.
Zurück zum Zitat K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2, 350 (2015). g7607 K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2, 350 (2015). g7607
31.
Zurück zum Zitat A.G. Tabak, M. Jokela, T.N. Akbaraly et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009)CrossRefPubMedPubMedCentral A.G. Tabak, M. Jokela, T.N. Akbaraly et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221 (2009)CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat E. Giovannucci, D. Michaud, The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132, 2208–2225 (2007)CrossRefPubMed E. Giovannucci, D. Michaud, The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132, 2208–2225 (2007)CrossRefPubMed
33.
Zurück zum Zitat J.A. Johnson, S.L. Bowker, Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25–31 (2011)CrossRefPubMed J.A. Johnson, S.L. Bowker, Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54, 25–31 (2011)CrossRefPubMed
34.
Zurück zum Zitat B.B. Barone, H.C. Yeh, C.F. Snyder et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33, 931–939 (2010)CrossRefPubMedPubMedCentral B.B. Barone, H.C. Yeh, C.F. Snyder et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33, 931–939 (2010)CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat B.B. Barone, H.C. Yeh, C.F. Snyder et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008)CrossRefPubMedPubMedCentral B.B. Barone, H.C. Yeh, C.F. Snyder et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008)CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat A.G. Renehan, H.C. Yeh, J.A. Johnson et al. Diabetes and cancer evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55, 1619–1632 (2012)CrossRefPubMed A.G. Renehan, H.C. Yeh, J.A. Johnson et al. Diabetes and cancer evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55, 1619–1632 (2012)CrossRefPubMed
37.
Zurück zum Zitat J.M. Baena-Díez, J. Peñafiel, I. Subirana et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 11, 1987–1995 (2016) J.M. Baena-Díez, J. Peñafiel, I. Subirana et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 11, 1987–1995 (2016)
38.
Zurück zum Zitat M. Tancredi, A. Rosengren, A.M. Svensson et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015)CrossRefPubMed M. Tancredi, A. Rosengren, A.M. Svensson et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015)CrossRefPubMed
39.
Zurück zum Zitat A. Rawshani, A.M. Svensson, B. Zethelius et al. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern. Med. 176(8), 1146–1154 (2016). 1CrossRefPubMed A. Rawshani, A.M. Svensson, B. Zethelius et al. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern. Med. 176(8), 1146–1154 (2016). 1CrossRefPubMed
40.
Zurück zum Zitat B. Carstensen, S.H. Read, S. Friis et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5), 980–988 (2016)CrossRefPubMedPubMedCentral B. Carstensen, S.H. Read, S. Friis et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5), 980–988 (2016)CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367–377 (2008)CrossRefPubMedPubMedCentral A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367–377 (2008)CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat I.J. Neeland, A.T. Turer, C.L. Ayers et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308, 1150–1159 (2012)CrossRefPubMedPubMedCentral I.J. Neeland, A.T. Turer, C.L. Ayers et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308, 1150–1159 (2012)CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat K. Bhaskaran, I. Douglas, H. Forbes et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384(9945), 755–765 (2014). 30CrossRefPubMedPubMedCentral K. Bhaskaran, I. Douglas, H. Forbes et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384(9945), 755–765 (2014). 30CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed
45.
Zurück zum Zitat X. Yang, G.T.C. Ko, W.Y. So et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59, 1254–1260 (2010)CrossRefPubMedPubMedCentral X. Yang, G.T.C. Ko, W.Y. So et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59, 1254–1260 (2010)CrossRefPubMedPubMedCentral
46.
47.
Zurück zum Zitat C. Hope, A. Robertshaw, K.L. Cheung et al. Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet. Med. 8, 1013–1025 (2016) C. Hope, A. Robertshaw, K.L. Cheung et al. Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet. Med. 8, 1013–1025 (2016)
48.
Zurück zum Zitat R. Vigneri, I.D. Goldfine, L. Frittitta, Insulin, insulin receptors, and cancer. J. Endocrinol. Invest. 12, 1365–1376 (2016) R. Vigneri, I.D. Goldfine, L. Frittitta, Insulin, insulin receptors, and cancer. J. Endocrinol. Invest. 12, 1365–1376 (2016)
49.
Zurück zum Zitat NCD Risk Factor Collaboration (NCD-RisC), Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387, 1377–1396 (2016)CrossRef NCD Risk Factor Collaboration (NCD-RisC), Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387, 1377–1396 (2016)CrossRef
50.
Zurück zum Zitat B. Lauby-Secretan, C. Scoccianti, D. Loomis et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 375(8), 794–798 (2016). 25CrossRefPubMedPubMedCentral B. Lauby-Secretan, C. Scoccianti, D. Loomis et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N. Engl. J. Med. 375(8), 794–798 (2016). 25CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat P.T. Campbell, Obesity: a certain and avoidable cause of cancer. Lancet 384(9945), 727–8 (2014). 30CrossRefPubMed P.T. Campbell, Obesity: a certain and avoidable cause of cancer. Lancet 384(9945), 727–8 (2014). 30CrossRefPubMed
52.
Zurück zum Zitat M. Arnold, M. Leitzmann, H. Freisling et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 41, 8–15 (2016)CrossRefPubMed M. Arnold, M. Leitzmann, H. Freisling et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 41, 8–15 (2016)CrossRefPubMed
53.
Zurück zum Zitat International Agency for Research on Cancer. IARC handbooks of cancer prevention: weight control and physical activity. (IARC Press, Lyon), (2002). Vol. 6 International Agency for Research on Cancer. IARC handbooks of cancer prevention: weight control and physical activity. (IARC Press, Lyon), (2002). Vol. 6
54.
Zurück zum Zitat A.G. Renehan, M. Tyson, M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–78 (2008)CrossRefPubMed A.G. Renehan, M. Tyson, M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–78 (2008)CrossRefPubMed
55.
Zurück zum Zitat N.M. Iyengar, C.A. Hudis, A.J. Dannenberg, Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297–309 (2015)CrossRefPubMed N.M. Iyengar, C.A. Hudis, A.J. Dannenberg, Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297–309 (2015)CrossRefPubMed
56.
Zurück zum Zitat S.D. Hursting, J. Digiovanni, A.J. Dannenberg et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5, 1260–1272 (2012)CrossRef S.D. Hursting, J. Digiovanni, A.J. Dannenberg et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5, 1260–1272 (2012)CrossRef
57.
Zurück zum Zitat N. Parekh, Y. Lin, R.B. Hayes et al. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4), 631–642 (2010)CrossRefPubMed N. Parekh, Y. Lin, R.B. Hayes et al. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4), 631–642 (2010)CrossRefPubMed
58.
Zurück zum Zitat M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004)CrossRefPubMed M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004)CrossRefPubMed
59.
Zurück zum Zitat K.K. Wong, J.A. Engelman, L.C. Cantley, Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87–90 (2010)CrossRefPubMed K.K. Wong, J.A. Engelman, L.C. Cantley, Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87–90 (2010)CrossRefPubMed
60.
Zurück zum Zitat R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011)CrossRefPubMed R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011)CrossRefPubMed
61.
Zurück zum Zitat E. Barrett-Connor, K.T. Khaw, S.S. Yen, Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 132, 895–901 (1990)CrossRefPubMed E. Barrett-Connor, K.T. Khaw, S.S. Yen, Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol. 132, 895–901 (1990)CrossRefPubMed
62.
Zurück zum Zitat D. Housa, J. Housova, Z. Vernerova, M. Haluzik, Adipocytokines and cancer. Physiol. Res. 55, 233–244 (2006)PubMed D. Housa, J. Housova, Z. Vernerova, M. Haluzik, Adipocytokines and cancer. Physiol. Res. 55, 233–244 (2006)PubMed
63.
Zurück zum Zitat A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436–444 (2008)CrossRefPubMed
64.
Zurück zum Zitat Y. Huang, X. Cai, M. Qiu et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57, 2261–2269 (2014)CrossRefPubMed Y. Huang, X. Cai, M. Qiu et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57, 2261–2269 (2014)CrossRefPubMed
65.
Zurück zum Zitat R.A. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108, 3B–24B (2011)CrossRefPubMed R.A. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108, 3B–24B (2011)CrossRefPubMed
66.
Zurück zum Zitat M. Buysschaert, J.L. Medina, M. Bergman, A. Shah, J. Lonier, Prediabetes and associated disorders. Endocrine 48(2), 371–393 (2015)CrossRefPubMed M. Buysschaert, J.L. Medina, M. Bergman, A. Shah, J. Lonier, Prediabetes and associated disorders. Endocrine 48(2), 371–393 (2015)CrossRefPubMed
67.
Zurück zum Zitat O. Tabak, R. Gelisgen, H. Erman et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin. Invest. Med. 34, E163–E171 (2011)CrossRefPubMed O. Tabak, R. Gelisgen, H. Erman et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin. Invest. Med. 34, E163–E171 (2011)CrossRefPubMed
68.
Zurück zum Zitat C.S. Pereira, P. Molz, R.P. Palazzo et al. DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat. Res. 753, 76–81 (2013)CrossRefPubMed C.S. Pereira, P. Molz, R.P. Palazzo et al. DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat. Res. 753, 76–81 (2013)CrossRefPubMed
69.
Zurück zum Zitat M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)CrossRef M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)CrossRef
70.
Zurück zum Zitat P. Stattin, O. Björ, P. Ferrari et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561–567 (2007)CrossRefPubMed P. Stattin, O. Björ, P. Ferrari et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30, 561–567 (2007)CrossRefPubMed
71.
Zurück zum Zitat M. Iwatsuki, K. Mimori, T. Yokobori et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101, 293–299 (2010)CrossRefPubMed M. Iwatsuki, K. Mimori, T. Yokobori et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101, 293–299 (2010)CrossRefPubMed
72.
Zurück zum Zitat X.H. Zhou, Q. Qiao, B. Zethelius et al. Diabetes, prediabetes and cancer mortality. Diabetologia 53, 1867–1876 (2010)CrossRefPubMed X.H. Zhou, Q. Qiao, B. Zethelius et al. Diabetes, prediabetes and cancer mortality. Diabetologia 53, 1867–1876 (2010)CrossRefPubMed
73.
Zurück zum Zitat S. Gao, A. Li, F. Liu et al. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24, 725–737 (2013)CrossRefPubMedPubMedCentral S. Gao, A. Li, F. Liu et al. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24, 725–737 (2013)CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat D. Giugliano, M.I. Maiorino, K. Esposito, Linking prediabetes and cancer: a complex issue. Diabetologia 58(1), 201–202 (2015)CrossRefPubMed D. Giugliano, M.I. Maiorino, K. Esposito, Linking prediabetes and cancer: a complex issue. Diabetologia 58(1), 201–202 (2015)CrossRefPubMed
75.
Zurück zum Zitat K.-H. Wagner, H. Brath, A global view on the development of non communicable diseases. Prev. Med. 54(suppl), S38–S41 (2012)CrossRefPubMed K.-H. Wagner, H. Brath, A global view on the development of non communicable diseases. Prev. Med. 54(suppl), S38–S41 (2012)CrossRefPubMed
76.
Zurück zum Zitat M. Aguilar, T. Bhuket, S. Torres et al. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313(19), 1973–1974 (2015). 19CrossRefPubMed M. Aguilar, T. Bhuket, S. Torres et al. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313(19), 1973–1974 (2015). 19CrossRefPubMed
77.
Zurück zum Zitat K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45(3), 362–364 (2014)CrossRefPubMed K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45(3), 362–364 (2014)CrossRefPubMed
78.
Zurück zum Zitat K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12), 1301–1309 (2013)CrossRefPubMed K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20(12), 1301–1309 (2013)CrossRefPubMed
79.
Zurück zum Zitat K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45(1), 28–36 (2014)CrossRefPubMed K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45(1), 28–36 (2014)CrossRefPubMed
80.
Zurück zum Zitat J.R. Jaggers, X. Sui, S.P. Hooker, M.J. LaMonte et al. Metabolic syndrome and risk of cancer mortality in men. Eur. J. Cancer 45, 1831–1838 (2009)CrossRefPubMedPubMedCentral J.R. Jaggers, X. Sui, S.P. Hooker, M.J. LaMonte et al. Metabolic syndrome and risk of cancer mortality in men. Eur. J. Cancer 45, 1831–1838 (2009)CrossRefPubMedPubMedCentral
81.
Zurück zum Zitat J.R. Zhou, G.L. Blackburn, W.A. Walker, Symposium introduction: metabolic syndrome and the onset of cancer. Am. J. Clin. Nutr. 86, s817–s819 (2007)CrossRefPubMed J.R. Zhou, G.L. Blackburn, W.A. Walker, Symposium introduction: metabolic syndrome and the onset of cancer. Am. J. Clin. Nutr. 86, s817–s819 (2007)CrossRefPubMed
82.
Zurück zum Zitat K. Esposito, P. Chiodini, A. Colao et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012)CrossRefPubMedPubMedCentral K. Esposito, P. Chiodini, A. Colao et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402–2411 (2012)CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat J.L. Harding, M. Sooriyakumaran, K.J. Anstey et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J. Hypertens. 34(1), 149–155 (2016)CrossRefPubMed J.L. Harding, M. Sooriyakumaran, K.J. Anstey et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J. Hypertens. 34(1), 149–155 (2016)CrossRefPubMed
84.
Zurück zum Zitat W.H. Chow, G. Gridley, J.F. Fraumani Jr, B. Jarvholm, Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000)CrossRefPubMed W.H. Chow, G. Gridley, J.F. Fraumani Jr, B. Jarvholm, Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311 (2000)CrossRefPubMed
85.
Zurück zum Zitat N.J. Kocher, C. Rjepaj, H. Robyak et al. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. (2016). doi:10.1007/s00345-016-1850-2 N.J. Kocher, C. Rjepaj, H. Robyak et al. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. (2016). doi:10.​1007/​s00345-016-1850-2
86.
Zurück zum Zitat N. Hayashi, M. Matsushima, T. Yamamoto et al. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 109(4), 515–519 (2012)CrossRefPubMed N. Hayashi, M. Matsushima, T. Yamamoto et al. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 109(4), 515–519 (2012)CrossRefPubMed
87.
Zurück zum Zitat H. Jafri, A.A. Alsheikh-Ali, R.H. Karas, Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipidaltering therapy. J. Am. Coll. Cardiol. 55, 2846–2854 (2010)CrossRefPubMed H. Jafri, A.A. Alsheikh-Ali, R.H. Karas, Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipidaltering therapy. J. Am. Coll. Cardiol. 55, 2846–2854 (2010)CrossRefPubMed
88.
Zurück zum Zitat M. Ezzati, E. Riboli, Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369, 954–964 (2013)CrossRefPubMed M. Ezzati, E. Riboli, Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369, 954–964 (2013)CrossRefPubMed
90.
Zurück zum Zitat C. Micucci, D. Valli, G. Matacchione, A. Catalano, Current perspectives between metabolic syndrome and cancer. Oncotarget. 25, 38959–38972 (2016) C. Micucci, D. Valli, G. Matacchione, A. Catalano, Current perspectives between metabolic syndrome and cancer. Oncotarget. 25, 38959–38972 (2016)
91.
Zurück zum Zitat P.C. Calder, N. Ahluwalia, F. Brouns et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 106(Suppl 3), S5–78 (2011)CrossRefPubMed P.C. Calder, N. Ahluwalia, F. Brouns et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 106(Suppl 3), S5–78 (2011)CrossRefPubMed
93.
Zurück zum Zitat F.E. Deng, N. Shivappa, Y. Tang et al. Association between diet-related inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on prediabetics: findings from NHANES III. Eur. J. Nutr. (2016). doi:10.1007/s00394-016-1158-4 F.E. Deng, N. Shivappa, Y. Tang et al. Association between diet-related inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on prediabetics: findings from NHANES III. Eur. J. Nutr. (2016). doi:10.​1007/​s00394-016-1158-4
94.
Zurück zum Zitat American Cancer Society. Cancer Facts and Figures 2012. (American Cancer Society, Atlanta, GA), (2012) American Cancer Society. Cancer Facts and Figures 2012. (American Cancer Society, Atlanta, GA), (2012)
95.
Zurück zum Zitat R. Doll, R. Peto, The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66, 1191–1308 (1981)CrossRefPubMed R. Doll, R. Peto, The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66, 1191–1308 (1981)CrossRefPubMed
96.
Zurück zum Zitat K. Esposito, D. Giugliano, Healthy lifestyle for metabolic health: no more excuse! Endocrine 46(2), 176–178 (2014)CrossRefPubMed K. Esposito, D. Giugliano, Healthy lifestyle for metabolic health: no more excuse! Endocrine 46(2), 176–178 (2014)CrossRefPubMed
97.
Zurück zum Zitat P.C. Hallal, L.B. Andersen, F.C. Bull, R. Guthold, W. Haskell, U. Ekelund, Lancet Physical Activity Series Working Group, Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380(9838), 247–257 (2012)CrossRefPubMed P.C. Hallal, L.B. Andersen, F.C. Bull, R. Guthold, W. Haskell, U. Ekelund, Lancet Physical Activity Series Working Group, Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380(9838), 247–257 (2012)CrossRefPubMed
98.
Zurück zum Zitat S.C. Moore, I.M. Lee, E. Weiderpass et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176(6), 816–825 (2016). 1CrossRefPubMedPubMedCentral S.C. Moore, I.M. Lee, E. Weiderpass et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176(6), 816–825 (2016). 1CrossRefPubMedPubMedCentral
Metadaten
Titel
Insights into the relationships between diabetes, prediabetes, and cancer
verfasst von
Lorenzo Scappaticcio
Maria Ida Maiorino
Giuseppe Bellastella
Dario Giugliano
Katherine Esposito
Publikationsdatum
31.12.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1216-y

Weitere Artikel der Ausgabe 2/2017

Endocrine 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.